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5,6-dimethylxanthenone-4-acetic acid, a novel antivascular anticancer drug, has completed Phase I clinical trial. Its actions in
mice include tumour necrosis factor induction, serotonin release, tumour blood ﬂow inhibition, and the induction of tumour
haemorrhagic necrosis and regression. We have used mice with a targeted disruption of the tumour necrosis factor receptor-
1 gene as recipients for the colon 38 carcinoma to determine the role of tumour necrosis factor signalling in the action of 5,6-
dimethylxanthenone-4-acetic acid. The pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid, as well as the degree of
induced plasma and tissue tumour necrosis factor, were similar in tumour necrosis factor receptor-1
7/7 and wild-type mice.
However, the maximum tolerated dose of 5,6-dimethylxanthenone-4-acetic acid was considerably higher in tumour necrosis
factor receptor-1
7/7 mice (4100 mg kg
71) than in wild-type mice (27.5 mg kg
71). The antitumour activity of 5,6-
dimethylxanthenone-4-acetic acid (25 mg kg
71) was strongly attenuated in tumour necrosis factor receptor-1
7/7 mice.
However, the reduced toxicity in tumour necrosis factor receptor-1
7/7 mice allowed the demonstration that at a higher
dose (50 mg kg
71), 5,6-dimethylxanthenone-4-acetic acid was curative and comparable in effect to that of a lower dose
(25 mg kg
71) in wild-type mice. The 5,6-dimethylxanthenone-4-acetic acid -induced rise in plasma 5-hydroxyindoleacetic acid,
used to reﬂect serotonin production in a vascular response, was larger in colon 38 tumour bearing than in non-tumour
bearing tumour necrosis factor receptor-1
7/7 mice, but in each case the response was smaller than the corresponding
response in wild-type mice. The results suggest an important role for tumour necrosis factor in mediating both the host
toxicity and antitumour activity of 5,6-dimethylxanthenone-4-acetic acid, but also suggest that tumour necrosis factor can be
replaced by other vasoactive factors in its antitumour action, an observation of relevance to current clinical studies.
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The tumour vasculature is a promising new target in cancer ther-
apy, and a number of antitumour agents have been identiﬁed that
either inhibit tumour angiogenesis (Baillie et al, 1995) or destroy
the tumour’s existing blood supply (Baguley, 2001). Tumour
necrosis factor (TNF), a pleiotropic cytokine that is produced
mainly by activated monocytes/macrophages, neutrophils, and T
cells (Balkwill, 1989), is thought to exert its antitumour effect
mainly through an antivascular mechanism. Flavone-8-acetic acid
(FAA), and its more potent analogue 5,6-dimethylxanthenone-4-
acetic acid (DMXAA), developed in this laboratory, are low mole-
cular weight antivascular agents that appear to exert their
antitumour effects at least partly through the induction of TNF
(Mace et al, 1990; Philpott et al, 1995). FAA proved to be inactive
in clinical studies (Kerr and Kaye, 1989), but DMXAA has shown
evidence of activity in a Phase I clinical trial (Jameson et al, 2000).
In mice DMXAA induces, in addition to TNF, serotonin (Bagu-
ley et al, 1997), nitric oxide (Thomsen et al, 1991), interferons,
interferon regulatory factors, and IP-10 (Cao et al, 2001). Like
FAA, DMXAA causes protracted inhibition of blood ﬂow in
murine tumours (Zwi et al, 1994; Lash et al, 1998) and induces
extensive tumour haemorrhagic necrosis that is similar to that
induced by TNF (Rewcastle et al, 1991). In situ hybridisation
studies indicate that both host and tumour cells within murine
colon 38 tumours express TNF mRNA after DMXAA treatment
(Joseph et al, 1999). An administration schedule of DMXAA
(two doses, 3 days apart) that increases TNF production also
improves antitumour activity (Philpott et al, 1995). Co-administra-
tion of thalidomide with DMXAA increases intratumoural TNF
synthesis and concomitantly increases cure rate (Ching et al,
1995; Browne et al, 1998; Cao et al, 1999).
While the above reports indicate that TNF induction is impor-
tant for the antitumour action of DMXAA, there is quite extensive
evidence that TNF-independent mechanisms may contribute to its
antitumour effect. A signiﬁcant decrease in tumour blood ﬂow is
observed within 1 h of administration of DMXAA, before detect-
able induction of cytokines (Zwi et al, 1994; Lash et al, 1998).
Induced endothelial cell apoptosis in tumour tissue occurs as early
as 15 min after DMXAA administration (Ching et al, 2002). Co-
administration of anti-TNF antibodies only partially reverses the
blood ﬂow and antitumour effects of DMXAA (Browne et al,
1998). Finally, DMXAA induces tumour haemorrhagic necrosis in
TNF knockout hosts (Ching et al, 1999).
The activities of TNF are mediated by binding to two receptors:
TNFR1 (p55), and TNFR2 (p75) (Aggarwal and Natarajan, 1996).
TNFR1 is ubiquitous except in erythrocytes and unstimulated T
cells, while TNFR2 is often more abundant on cells of haemopoie-
tic lineage and is also expressed on endothelium (Slowik et al,
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cells of the tumour vasculature are the targets of TNF-induced
necrosis (Stoelcker et al, 2000). In the present study, we have
sought to evaluate the role of TNF in the host response to DMXAA
by utilising mice with targeted disruption of TNF receptor I gene
(TNFR1
7/7) as recipients for the (TNF positive) colon 38 carcino-
ma. We have examined four end-points, toxicity, tumour growth
delay, induction of tumour haemorrhagic necrosis, and serotonin
production. Because DMXAA pharmacokinetics are of major
importance in the interpretation of experiments combining
DMXAA with drugs such as thalidomide (Kestell et al, 2000) and
cyproheptadine (Zhao et al, 2001), we also measured drug pharma-
cokinetics in wild-type (WT) and TNFR1
7/7 mice.
MATERIALS AND METHODS
Mice and tumour model
Breeding stocks of C57Bl/6 and TNFR1
7/7 mice on a C57Bl back-
ground were obtained from Jackson Laboratories, Bar Harbor,
Maine, USA. WT and TNFR1
7/7 mice were bred in the Animal
Resources Unit, University of Auckland (TNFR1
7/7 mice under
speciﬁc pathogen-free conditions). All experiments were approved
by the University of Auckland Animal Ethics Committee, and
conformed to the Guidelines for the Welfare of Animals in Experi-
mental Neoplasia, as set out by the United Kingdom Co-ordinating
Committee on Cancer Research. Mice were used between 6 and 12
weeks of age and the colon 38 tumour was implanted subcuta-
neously in mice that had been anaesthetised by intraperitoneal
(i.p.) administration of pentobarbitone (87 mg kg
71). DMXAA
was synthesised in this laboratory (Rewcastle et al, 1991), dissolved
in sterile saline, protected from light (Rewcastle et al, 1990), and
administered i.p. (10 mlg
71 body weight).
Tumour growth delay and tumour necrosis determination
Mice were treated i.p. with DMXAA when the tumours were
approximately 5 mm in diameter. Tumour size was measured
thrice weekly using callipers and the volumes calculated as
0.526a
26b, where a and b were the minor and major tumour
axes. The arithmetic means and standard error of the means were
calculated for each time point, counting cured animals as having
zero tumour volume, and expressed as fractions of the pre-treat-
ment tumour volume. Growth delay was determined as the
difference in the number of days required for the untreated and
treated tumours to reach four times the pre-treatment volume.
Tumour necrosis was measured in WT and TNFR1
7/7 mice in
which colon 38 tumours had been implanted and allowed to grow
to a diameter of approximately 6 mm. Tumours were removed
24 h after drug treatment, ﬁxed in 10% formalin, sectioned and
stained with haematoxylin/eosin. Tumour necrosis was quantiﬁed
microscopically using a grid system (Baguley et al, 1989).
TNF assay
Mice were anaesthetised with halothane and bled from the ocular
sinus. The blood was allowed to coagulate overnight on ice. After
centrifugation of samples (2000 g, 30 min, 48C) the serum was
then removed and stored at 7708C. Tumour, spleen and liver
tissues were homogenised in 1.5 ml of a-MEM medium using a
tissue homogeniser. The homogenates were centrifuged (2000 g,
30 min, 48C) and the supernatant was removed and re-centrifuged
(14000 g, 30 min at 48C). Serum and supernatants from tissue
homogenates were kept at 7708C until use. TNF was assayed using
a commercially available ELISA kit (OptEIA Mouse TNF kit, Phar-
Mingen, San Diego, CA, USA) according to the manufacturer’s
directions.
5-hydroxyindoleacetic acid (5HIAA) assay
Blood samples (700–800 ml) from DMXAA-treated and untreated
mice were collected from the ocular sinus into heparinised tubes
during halothane anaesthesia, centrifuged, and the plasma was
removed and mixed with 0.1 M HCl containing 0.01% ascorbic
acid. 5HIAA concentrations were measured using automated solid
phase extraction and high performance liquid chromatography
(HPLC) as previously described (Zhao et al, 2001).
DMXAA assay
Tumour-bearing mice (three per group) were treated with DMXAA
(25 mg kg
71 i.p.). After 0.25, 1, 2, 3, 8 and 24 h, blood samples
(700–800 ml) were collected from the ocular sinus into heparinised
tubes during halothane anaesthesia, centrifuged, and the plasma
was removed and stored at 7208C until analysis. DMXAA plasma
concentrations were measured using automated solid phase extrac-
tion and high performance liquid chromatography (HPLC) as
previously described (Kestell et al, 2000).
RESULTS
TNF production in response to DMXAA
The maximum tolerated doses (MTD) of DMXAA in TNFR1
7/7
mice was determined and found to be much higher in TNFR1
7/
7 mice than in WT mice (Table 1). The capacity of DMXAA to
induce TNF was compared 2 h after treatment with DMXAA at
doses of up to 100 mg kg
71. The maximal dose was considerably
greater than the MTD in WT mice (Table 1), but could be used
because it has been shown previously (Philpott et al, 1995) that
no signs of distress occur within the time period of the experiment.
DMXAA induced similar TNF activity in WT and TNFR1
7/7
mice, with maximal activity at 75 mg kg
71 (Figure 1). The TNF
response in tumour tissue was considerably higher than that in
serum. The response in liver tissue was small, while that in spleen
was intermediate between those in tumour and liver (Figure 1).
Antitumour activity
The responses to DMXAA of colon 38 tumours growing in WT
and TNFR1
7/7 mice were compared. In WT mice, DMXAA (25
and 27.5 mg kg
71) produced growth delays of 13 and 19 days,
respectively, and cure rates of 40% (Figure 2A; Table 2). In
TNFR1
7/7 mice, DMXAA (25 mg kg
71) induced only a short
tumour growth delay (4 days) with no cures. However, a higher
dose (50 mg kg
71) induced a tumour growth delay of 13 days
and a cure rate of 60% (Figure 2B; Table 2), similar to that
induced by a dose of 25 mg kg
71 in WT mice.
Induction of haemorrhagic necrosis
Colon 38 tumours growing in WT and TNFR1
7/7 mice were
removed and examined 24 h after treatment with DMXAA
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Table 1 Maximum tolerated dose (MTD) of DMXAA.
Strain Tumour
MTD
mg kg
71
WT No 30
WT Yes 27.5
TNFR1
7/7 No 5100
TNFR1
7/7 Yes 5100
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71). Tumours from untreated WT and TNFR1
7/7 mice
showed either little necrosis or central necrosis occupying up to
30% of the section area. Tumours from DMXAA-treated WT
and TNFR1
7/7 mice showed extensive areas of haemorrhagic
necrosis that were identical in histological appearance. The propor-
tion of tumour haemorrhagic necrosis in mice treated with
DMXAA (25 mg kg
71) was 99% in WT and 76% in TNFR1
7/7
mice, but at higher doses, tumours in TNFR1
7/7 mice exhibited
a similar degree of necrosis (Table 2).
5HIAA response
Previous studies in our laboratory have shown that treatment of
mice with antivascular agents induces the accumulation in plas-
ma of serotonin and its metabolite 5HIAA (Baguley et al,
1997). 5HIAA is the preferred marker for routine assay because
of its greater stability (Kestell et al, 2001). Administration of
DMXAA (25 mg kg
71) to non-tumour bearing WT mice
produced a signiﬁcant (P50.001) increase in 5HIAA after
30 min, followed by a further increase to a maximum after
4 h and a decrease thereafter. Administration to non-tumour
TNFR1
7/7 mice also produced a signiﬁcant increase in 5HIAA
after 15 min (P=0.001) and 60 min (P50.001) but no further
increase thereafter (Figure 3A). Administration of DMXAA to
colon 38 tumour bearing WT mice caused plasma 5HIAA
concentrations to rise continuously over the 24-h period of
measurement, as shown previously (Zhao et al, 2002). In
contrast, administration of DMXAA to tumour bearing
TNFR1
7/7 mice caused plasma 5HIAA to increase over 3 h
but to decline at later times (Figure 3B). The dose response
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Figure 1 Dose response for TNF induction by DMXAA. TNF activity in serum, colon 38 tumour, spleen, and liver of WT and TNFR1
7/7 mice, untreated
or 2 h after treatment with a range of DMXAA doses, was measured by ELISA assay and expressed as the mean+s.e. (n=3).
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Figure 2 Growth of colon 38 tumours in WT (A) and TNFR1
7/7 (B) mice. Tumor volumes in mice without treatment, or following treatment with
DMXAA at doses of 25, 27.5 and 50 mg kg
71 were expressed as the mean+s.e. (n=5).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 465–470of plasma 5HIAA in TNFR1
7/7 mice was measured 24 h after
administration of DMXAA, and was found to increase with
dose up to 100 mg kg
71. The response was generally greater
in tumour bearing mice than in non-tumour bearing mice
(Figure 3C).
Pharmacokinetics of DMXAA
To determine whether the difference in antitumour activity of
DMXAA in WT and TNFR1
7/7 mice was inﬂuenced by altered
DMXAA pharmacokinetics, we compared DMXAA plasma
concentration-time proﬁles in WT and TNFR1
7/7 colon 38
tumour-bearing mice up to 8 h after DMXAA administration
(25 mg kg
71) (Figure 4). The plasma Cmax values in WT
and TNFR1
7/7 mice, 530+39 and 411+53 mmol l
71 respec-
tively, as well as plasma concentrations at other times, were
not signiﬁcantly different. The corresponding plasma half-lives
were 2.6 h and 2.8 h respectively, and the areas under the
concentration-time curves (AUC) were 1623 and
1609 mmol.h l
71, respectively.
DISCUSSION
One of the most unusual properties of DMXAA is its ability, as a
low molecular weight drug, to induce the cytokine TNF in both
plasma and tumour tissue (Philpott et al, 1995; Cao et al, 1999).
The results described here provide two novel ﬁndings on the role
of TNF in this action. The ﬁrst is that the MTD of DMXAA is
much higher in TNFR1
7/7 mice (Table 1), suggesting a critical
role for TNF in host toxicity. The second is that DMXAA can
induce TNFR1-independent cures of colon 38 tumours. The results
extend two previous studies, one using anti-TNF antibody (Browne
et al, 1998) and one using TNF knockout mice (Ching et al, 1999),
which raised the question of whether TNF is essential for antitu-
mour activity.
The mechanism of DMXAA host toxicity has not yet been
clearly deﬁned but studies of tissue pathology in mice treated with
DMXAA indicate that vascular damage can occur, particularly in
tissues with a low vascular density such as peripheral lymphoid
tissues, the thymus gland and the uterus (Zwi et al, 1990). Mice
administered DMXAA at the MTD may exhibit sluggish move-
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Table 2 Antitumour responses to DMXAA in WT and TNFR1
7/7 mice
WT mice TNFR1
7/7 mice
Dose
(mg kg
71)
Growth
a delay
(days)
Cures
a
(%)
Necrosis
b
(%)
5HIAA
b
(nM)
Growth
a delay
(days)
Cures
a
(%)
Necrosis
b
(%)
5HIAA
b
(nM)
00 0 2 6 +6 262+42 0 0 11+3 328+137
25 13 40 99+0.3 1964+16 4 0 76+14 334+45
25 11 40 ND
c ND 5 0 ND ND
27.5 19 40 ND ND ND ND ND ND
50 13 60 98+2 670+52
75 ND ND 99+0.3 767+120
100 ND ND 100+0 1350+75
aGrowth delays and cures include data from Figure 2 and from one independent experiment.
bColon 38 tumour haemorrhagic necrosis and plasma 5HIAA in tumour-bearing
mice were measured 24 h after treatment with DMXAA and expressed as the mean+s.e. (n=3–6).
cND=Not determined.
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Figure 3 Plasma 5HIAA responses following administration of DMXAA. (A) Time course of 5HIAA response of non-tumour bearing WT mice treated
with DMXAA (30 mg kg
71) and non-tumour bearing TNFR1
7/7 mice treated with DMXAA (25 mg kg
71). (B) Time course of 5HIAA response of colon
38-tumour bearing TNFR1
7/7 mice treated with DMXAA (25 mg kg
71). Previously published data (Zhao et al, 2002) for tumour bearing WT mice
treated with DMXAA (25 mg kg
71) is shown for comparison. (C) Dose dependence of 5HIAA response (24 h after administration of DMXAA) for
TNFR1
7/7 mice without or with colon 38 tumours. Each point represents the mean+s.e. (n53).
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(unpublished data), and the lack of such symptoms in TNFR1
7/7
mice suggests that TNFR1 receptors on the vascular endothelium,
may be a major mediator of this toxicity of DMXAA. The toxic
effects of DMXAA in WT mice are consistent with changes to
normal vascular endothelium causing reduced peripheral blood
ﬂow and oedema. Possible mechanisms include TNF-induced
increases in vascular permeability (Royall et al, 1989) and TNF-
induced apoptosis of normal endothelial cells, which has been
observed both in vitro and in vivo (Polunovsky et al, 1994; Mess-
mer et al, 1999).
The induction of host antivascular effects might arise from a
direct effect of DMXAA on the vascular endothelium, for instance
by changed vascular permeability (Baguley, 2001) or by induced
apoptosis of vascular endothelial cells (Ching et al, 2002). In addi-
tion, the antivascular effects may occur indirectly through the
production of TNF (Baguley, 2001). One feature of the action of
a variety of antivascular drugs is their induction of serotonin
release into plasma (Baguley et al, 1997). The use of TNFR1
7/7
mice, together with monitoring of plasma 5HIAA as a more stable
metabolite of serotonin (Kestell et al, 2001), provides an opportu-
nity to estimate the relative contributions of the direct and indirect
effects of DMXAA. The similarity of DMXAA pharmacokinetics in
WT and TNFR1
7/7 mice (Figure 4), together with the similarity
of intratumoural TNF production at the same DMXAA dose
(Figure 1), are important for this comparison to be made. As
shown in Figure 2A, DMXAA induces a plasma 5HIAA response
in TNFR1
7/7 mice at early times (within 15 min), indicating a
TNF-independent vascular effect and consistent with the hypothesis
that DMXAA can cause direct damage to the vascular endothelium
(Ching et al, 2002). The 5HIAA response in WT mice also occurs
early, but this is followed by a larger maximal response, consistent
with it being a composite of both direct and TNF-mediated effects.
The 5HIAA responses of tumour-bearing TNFR1
7/7 mice also
provide information on the role of vascular effects in the antitu-
mour response to DMXAA. As shown in Figure 2B, the response
of WT mice to DMXAA (25 mg kg
71) is sustained for at least
24 h, consistent with the presence of an extended, tumour-speciﬁc
vascular response. This sustained response is lacking in TNFR1
7/
7 mice treated at the same dose, in agreement with the reduced
induction of tumour haemorrhagic necrosis and smaller induced
tumour growth delay (Figure 2; Table 2). The results support the
concept that the late, tumour-speciﬁc vascular response in WT mice
treated at this dose is TNF-dependent. TNF may increase vascular
permeability (Royall et al, 1989) as well as induce endothelial cell
apoptosis (Polunovsky et al, 1994; Messmer et al, 1999), possibly
mediated by reduced avb3 integrin-mediated tumour endothelial
cell adhesion (Ruegg et al, 1998). A higher dose of DMXAA does
induce tumour regressions in TNFR1
7/7 mice (Table 2) and
although time courses for 5HIAA production at higher doses have
not been carried out, the dose response measured after 24 h
increases markedly (Figure 2C), consistent with the generation of
a sustained 5HIAA response in TNFR1
7/7 mice at high dose.
In conclusion, the demonstration that at a dose of 50 mg kg
71,
DMXAA demonstrates excellent antitumour activity in TNFR1
7/7
mice without host toxicity (Figure 2; Table 1) suggests that other
cytokines or vasoactive agents are induced by DMXAA and can
substitute for TNF. The nature of the agent(s) involved is currently
unknown, but other agents known to induce tumour haemorrhagic
necrosis include interferons a/b (Dvorak and Gresser, 1989), inter-
leukin-1a (Johnson et al, 1991), IP-10 (Sgadari et al, 1996),
serotonin (Manda et al, 1988) and nitric oxide (Fukumura et al,
1997). DMXAA is known to induce interferons (Pang et al,
1998), IP-10 (Cao et al, 2001), serotonin (Baguley et al, 1993,
1997) and nitric oxide (Thomsen et al, 1991). Phase I trials of
DMXAA show evidence of decreased tumour blood ﬂow (Rustin
et al, 1998; Jameson et al, 2000) and increased plasma 5HIAA
(Kestell et al, 2001), but only a small increase in plasma nitrate
and no increase in plasma TNF (Jameson et al, 2000). It is possible
that other DMXAA-inducible cytokines are involved in humans,
and their identiﬁcation is an important consideration in future
clinical trials.
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